Biovie Inc (BIVI) - Net Assets
Based on the latest financial reports, Biovie Inc (BIVI) has net assets worth $19.27 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.50 Million) and total liabilities ($3.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check BIVI financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $19.27 Million |
| % of Total Assets | 85.61% |
| Annual Growth Rate | 35.63% |
| 5-Year Change | 276.45% |
| 10-Year Change | 892.31% |
| Growth Volatility | 679.26 |
Biovie Inc - Net Assets Trend (2013–2025)
This chart illustrates how Biovie Inc's net assets have evolved over time, based on quarterly financial data. Also explore Biovie Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for Biovie Inc (2013–2025)
The table below shows the annual net assets of Biovie Inc from 2013 to 2025. For live valuation and market cap data, see BIVI market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $19.01 Million | +22.61% |
| 2024-06-30 | $15.51 Million | +1.08% |
| 2023-06-30 | $15.34 Million | +317.88% |
| 2022-06-30 | $3.67 Million | -27.31% |
| 2021-06-30 | $5.05 Million | +123.49% |
| 2020-06-30 | $-21.50 Million | -1108.90% |
| 2019-06-30 | $2.13 Million | +1816.30% |
| 2018-06-30 | $111.20K | -90.39% |
| 2017-06-30 | $1.16 Million | -39.60% |
| 2016-06-30 | $1.92 Million | +3640.23% |
| 2015-06-30 | $-54.12K | -131.58% |
| 2014-06-30 | $171.39K | -65.07% |
| 2013-06-30 | $490.70K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biovie Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35212673600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.48K | 0.04% |
| Other Components | $371.15 Million | 1952.18% |
| Total Equity | $19.01 Million | 100.00% |
Biovie Inc Competitors by Market Cap
The table below lists competitors of Biovie Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sirona Biochem Corp
V:SBM
|
$11.23 Million |
|
Max Resource Corp
V:MAX
|
$11.24 Million |
|
Annexin Pharmaceuticals AB
ST:ANNX
|
$11.24 Million |
|
Delixy Holdings Limited Ordinary Shares
NASDAQ:DLXY
|
$11.24 Million |
|
Calibre
PA:ALWIN
|
$11.23 Million |
|
Superior Resources Ltd
AU:SPQ
|
$11.21 Million |
|
COCRYSTAL PHARMA NEW O.N.
F:8CC
|
$11.21 Million |
|
GPM Metals Inc
V:GPM
|
$11.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biovie Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 15,506,215 to 19,011,985, a change of 3,505,770 (22.6%).
- Net loss of 17,542,120 reduced equity.
- Dividend payments of 369,465,000,000 reduced retained earnings.
- New share issuances of 15,674,613 increased equity.
- Other factors increased equity by 369,470,373,277.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.54 Million | -92.27% |
| Dividends Paid | $369.46 Billion | -1943326.8% |
| Share Issuances | $15.67 Million | +82.45% |
| Other Changes | $369.47 Billion | +1943355.06% |
| Total Change | $- | 22.61% |
Book Value vs Market Value Analysis
This analysis compares Biovie Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.13x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.13x to 0.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-06-30 | $1.49 | $1.68 | x |
| 2014-06-30 | $24.60 | $1.68 | x |
| 2015-06-30 | $-7.76 | $1.68 | x |
| 2016-06-30 | $274.65 | $1.68 | x |
| 2017-06-30 | $161.83 | $1.68 | x |
| 2018-06-30 | $14.52 | $1.68 | x |
| 2019-06-30 | $83.91 | $1.68 | x |
| 2020-06-30 | $-436.12 | $1.68 | x |
| 2021-06-30 | $40.72 | $1.68 | x |
| 2022-06-30 | $14.88 | $1.68 | x |
| 2023-06-30 | $47.23 | $1.68 | x |
| 2024-06-30 | $34.32 | $1.68 | x |
| 2025-06-30 | $12.87 | $1.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biovie Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -92.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-92.27%) is above the historical average (-503.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -14.27% | 0.00% | 0.00x | 1.03x | $-119.11K |
| 2014 | -187.82% | 0.00% | 0.00x | 1.94x | $-339.03K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-227.60K |
| 2016 | -22.54% | 0.00% | 0.00x | 1.42x | $-623.52K |
| 2017 | -115.01% | 0.00% | 0.00x | 2.04x | $-1.45 Million |
| 2018 | -2169.98% | 0.00% | 0.00x | 19.56x | $-2.42 Million |
| 2019 | -114.69% | 0.00% | 0.00x | 1.21x | $-2.66 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.53 Million |
| 2021 | -2579.03% | 0.00% | 0.00x | 1.20x | $-130.75 Million |
| 2022 | -710.57% | 0.00% | 0.00x | 5.48x | $-26.45 Million |
| 2023 | -327.61% | 0.00% | 0.00x | 2.29x | $-51.79 Million |
| 2024 | -207.15% | 0.00% | 0.00x | 1.63x | $-33.67 Million |
| 2025 | -92.27% | 0.00% | 0.00x | 1.13x | $-19.44 Million |
Industry Comparison
This section compares Biovie Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biovie Inc (BIVI) | $19.27 Million | -14.27% | 0.17x | $11.23 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more